Krystal Biotech
Krystal Biotech is a United States-based biotechnology company running 2 late-stage cancer trials of KB707 in non-small-cell lung cancer and melanoma.
Overview
Krystal Biotech, based in Pittsburgh, the United States, is a biotechnology company listed as NASDAQ: KRYS. Krystal Biotech develops redosable genetic medicines using a proprietary, replication-defective, non-integrating modified HSV-1 vector platform for severe, life-threatening or rare diseases. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing KB707 in non-small-cell lung cancer and melanoma. The largest, NCT06228326 (A Study Assessing KB707 for the Treatment of Advanced Solid Tumour Malignancies Affecting the Lungs), plans to enrol 250 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry, checked on 2026-09-11; company facts are from the official website.
Similar pages
not linked directly; found by shared links- CompanymAbxience Research S.L.
Shares Melanoma, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyMultitude Therapeutics
Shares Melanoma, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyiOnctura
Shares Melanoma, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyGeorgiamune
Shares Melanoma and the tag ctgov-sponsor.
- CompanyAvistone Biotechnology
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyMaia Biotechnology
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyShanghai Juncell Therapeutics
Shares Melanoma, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanySTCube
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.